<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941976</url>
  </required_header>
  <id_info>
    <org_study_id>030(Z)WO19176</org_study_id>
    <secondary_id>2019-003257-29</secondary_id>
    <nct_id>NCT04941976</nct_id>
  </id_info>
  <brief_title>Benzydamine in Sore Throat Pain Relief (BePaiR Study)</brief_title>
  <acronym>BePaiR</acronym>
  <official_title>Phase IV Study Comparing the Efficacy and Safety of Benzydamine Hydrochloride 0,3% Oromucosal Spray and Benzydamine Hydrochloride 3 mg Lozenges in Patients With Acute Sore Throat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aziende Chimiche Riunite Angelini Francesco S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Zak-Pharma Dienstleistung Ges.m.b.H.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aziende Chimiche Riunite Angelini Francesco S.p.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to generate new clinical data about the speed of relief provided by&#xD;
      a single application of Benzydamine hydrochloride 0,3% oromucosal spray vs Benzydamine&#xD;
      hydrochloride 3 mg lozenges mint flavour.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy and safety of benzydamine local-applied, in the treatment of various throat&#xD;
      inflammatory and painful conditions, had been widely demonstrated.&#xD;
&#xD;
      The aim of this study is to generate new clinical data about the speed of relief provided by&#xD;
      a single application of Benzydamine hydrochloride 0,3% oromucosal spray or Benzydamine&#xD;
      hydrochloride 3 mg lozenges mint flavour.&#xD;
&#xD;
      The study will be conducted at 15 sites located among Poland, Hungary and Russia (5 sites for&#xD;
      each country).&#xD;
&#xD;
      356 patients affected by acute sore throat will be enrolled in out-patient clinics or&#xD;
      out-patient departments of city hospitals.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2020</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicenter, randomised, active-controlled, open label, parallel-group, international study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of responders at 2 min</measure>
    <time_frame>2 minutes</time_frame>
    <description>Percentage of responders defined as patients reported at least a &quot;slight relief&quot; using Sore Throat Relief Rating Scale at 2 minutes after the first application of benzydamine hydrochloride 0.3% spray or benzydamine hydrochloride 3mg lozenges.&#xD;
A score ≥1 in Sore Throat Relief Rating Scal is considered as the first perceived pain relief or &quot;slight relief&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of responders at 1 min</measure>
    <time_frame>1 minute</time_frame>
    <description>Percentage of responders defined as patients reported at least a &quot;slight relief&quot; using Sore Throat Relief Rating Scale at 1 minute after the first application of benzydamine hydrochloride 0.3% spray or benzydamine hydrochloride 3mg lozenges.&#xD;
A score ≥1 in Sore Throat Relief Rating Scal is considered as the first perceived pain relief or &quot;slight relief&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients recording a meaningful sore throat relief</measure>
    <time_frame>5,10,15,30,60 and 120 minutes</time_frame>
    <description>The meaningful sore throat relief is assessed after a single dose administration.&#xD;
A &quot;meaningful sore throat relief&quot; is considered as a score ≥ 3 (moderate relief) in the Sore Throat Relief Rating Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sore Throat Relief Rating Scale.</measure>
    <time_frame>1, 2, 5,10,15,30,60,120,240 minutes</time_frame>
    <description>Change from 1 minute up to 4 hours post-dose in Sore Throat Relief Rating Scale.The Sore Throat Relief Rating Scale is a 7-point categorical scale that assesses the local analgesic effect starting from: 0= &quot;no relief&quot; up t 7=&quot;complete relief&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in sore throat pain intensity.</measure>
    <time_frame>Baseline, 7 day</time_frame>
    <description>Change in sore throat pain intensity from baseline up to 7 days of treatment through the Sore Throat Pain Intensity Scale assessment. The Sore Throat Pain Intensity Scale is a visual analogic scale (VAS) assessing the intensity of the Sore Throat. It consists of a continuous horizontal line of 100 mm in length with ends labelled as the extremes of pain, from 0 (left side): &quot;no pain&quot;, to 10 (right side): &quot;pain as bad as it could be&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">356</enrollment>
  <condition>Acute Sore Throat</condition>
  <arm_group>
    <arm_group_label>0.3% benzydamine hydrochloride spray oromucosal solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single application of 0.3% benzydamine hydrochloride spray oromucosal solution, corresponding to 2.04 mg of benzydamine (4 nebulizations)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A single 3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.3% benzydamine hydrochloride spray oromucosal solution</intervention_name>
    <description>Single application of 0.3% benzydamine hydrochloride spray oromucosal solution. Drug applications will be performed at the investigational site, on the morning of Visit 0.&#xD;
In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.</description>
    <arm_group_label>0.3% benzydamine hydrochloride spray oromucosal solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single 3 mg lozenge of benzydamine hydrochloride (mint flavour)</intervention_name>
    <description>Single 3 mg lozenge of benzydamine hydrochloride (mint flavour). Drug applications will be performed at the investigational site, on the morning of Visit 0.&#xD;
In case of persistent sore throat patients will continue the assigned treatment at home, according to the local SmPC and up to one week, until the symptoms' resolution.</description>
    <arm_group_label>3 mg lozenge of benzydamine hydrochloride (mint flavour), corresponding to 2.68 mg of benzydamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male and female patients (aged 18 - 75 years, limits included) with recent onset&#xD;
             (≤3 days) of sore throat and a diagnosis of tonsillopharyngitis confirmed by:&#xD;
&#xD;
               1. Presence of at least one symptom of URTI in the previous 24 h on the URTI&#xD;
                  questionnaire;&#xD;
&#xD;
               2. Sore throat pain intensity score ≥ 60 mm on Sore Throat Pain Intensity Scale&#xD;
                  (STPIS);&#xD;
&#xD;
               3. A score ≥ 5 on Tonsillo-Pharingytis Assessment (TPA);&#xD;
&#xD;
          -  Women of childbearing potential or with no menses for a period &lt; 12 months must have a&#xD;
             negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the&#xD;
             signature of the informed consent up to the Visit 2, using an appropriate birth&#xD;
             control method such as combined oestrogen-progestin containing hormonal contraceptives&#xD;
             (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g.,&#xD;
             oral, injectable, implantable), intrauterine device (IUD) or Intrauterine&#xD;
             hormone-releasing System (IUS) in combination with male condom, bilateral tubal&#xD;
             occlusion, vasectomised partner, sexual abstinence. The following definitions will be&#xD;
             considered:&#xD;
&#xD;
               -  Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and&#xD;
                  until becoming post-menopausal, unless permanently sterile. Permanent&#xD;
                  sterilization methods include hysterectomy, bilateral salpingectomy and bilateral&#xD;
                  oophorectomy.&#xD;
&#xD;
          -  Patients legally capable of giving their consent to participate in the study&#xD;
             (including personal data processing) and available to sign and date the written&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to benzydamine or its excipients;&#xD;
&#xD;
          -  Phenylketonuria;&#xD;
&#xD;
          -  Clinically significant abnormalities at physical examination and vital signs;&#xD;
&#xD;
          -  Intolerance to acetylsalicylic acid or other NSAIDS;&#xD;
&#xD;
          -  History or diagnosis of asthma;&#xD;
&#xD;
          -  Any concomitant disease that compromise breathing (i.e. bronchopneumonia);&#xD;
&#xD;
          -  Mouth breathing due to nasal congestion which causes throat drying;&#xD;
&#xD;
          -  Severe coughing which causes throat discomfort;&#xD;
&#xD;
          -  Purulent plaques on the tonsils;&#xD;
&#xD;
          -  Any inhaled therapy in the previous week before the first drug administration;&#xD;
&#xD;
          -  Use of antibiotics for an acute disease in the 7 days before randomisation (chronic&#xD;
             antibiotic use, such as for acne, is acceptable); any sustained release analgesic&#xD;
             within 24 hours of administration of study medication; any medications for cold and&#xD;
             flu (i.e., decongestants, antihistamines, expectorants, antitussives), immediate&#xD;
             release analgesic or antipyretic within 4 hours of administration of study medication;&#xD;
&#xD;
          -  Use of any lozenge, mouthwash, spray or menthol-containing products within 2 hours of&#xD;
             administration of study medication;&#xD;
&#xD;
          -  Women during pregnancy or lactation period;&#xD;
&#xD;
          -  Subject involved in the conduct of the study (e.g. Investigator or his/her deputy,&#xD;
             first grade relatives, pharmacist, assistant or other personnel, etc);&#xD;
&#xD;
          -  Participation to a clinical trial within 3 months prior to the inclusion in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Háziorvosi Rendelő</name>
      <address>
        <city>Budapest</city>
        <zip>H-1082</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Háziorvosi Rendelő</name>
      <address>
        <city>Budapest</city>
        <zip>H-1138</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Háziorvosi Rendelő</name>
      <address>
        <city>Pilisvörösvár</city>
        <zip>H-2085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Háziorvosi Rendelő</name>
      <address>
        <city>Tárnok</city>
        <zip>H-2461</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Háziorvosi Rendelő</name>
      <address>
        <city>Érd</city>
        <zip>H-2030</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Zdrowia i Profilaktyki Dabie Filia</name>
      <address>
        <city>Krakow</city>
        <zip>31-422</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Centrum Zdrowia i Profilaktyki Dabie Krakow</name>
      <address>
        <city>Krakow</city>
        <zip>31-567</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ValeoMedical</name>
      <address>
        <city>Lodz</city>
        <zip>94-004</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zdrowa Rodzina Przychodnia Lekarska</name>
      <address>
        <city>Warszawa</city>
        <zip>02-785</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Przchodnia Orlik</name>
      <address>
        <city>Warszawa</city>
        <zip>04-041</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific research center Eco-Safety, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>191119</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scientific research center Eco-Safety, LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Healthcare Institution &quot;Clinical Hospital &quot;RZD-Medicine&quot; St.Petersburg&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint-Petersburg State Budgetary Healthcare Institution &quot;City outpatient clinic #106&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital &quot;OrKli&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199178</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Astarta&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199226</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Meili&quot; LLC</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199405</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oromucosal spray</keyword>
  <keyword>lozenges</keyword>
  <keyword>Benzydamine hydrochloride 0.3%</keyword>
  <keyword>Benzidamine hydrochloride 3 mg</keyword>
  <keyword>acute sore throat</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharyngitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzydamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

